司帕沙星纸片扩散法药敏试验的暂行解释标准。
Tentative interpretive criteria for disk diffusion susceptibility testing of sparfloxacin.
作者信息
Fuchs P C, Barry A L, Pfaller M A
机构信息
St. Vincent Hospital and Medical Center, Portland, Oregon 97225.
出版信息
J Clin Microbiol. 1993 Aug;31(8):2236-7. doi: 10.1128/jcm.31.8.2236-2237.1993.
Abstract
Susceptibility to sparfloxacin was tested simultaneously by the agar dilution and disk diffusion methods. For tests with 5-micrograms sparfloxacin disks, we propose that the breakpoints for the susceptibility and resistance categories should be > or = 19 and < or = 15 mm, respectively. Most minor discrepancies involved tests with pseudomonads.
摘要
采用琼脂稀释法和纸片扩散法同时检测对司帕沙星的敏感性。对于使用5微克司帕沙星纸片的试验，我们建议，敏感和耐药分类的断点分别应为≥19毫米和≤15毫米。大多数微小差异涉及假单胞菌的检测。
相似文献
1
Tentative interpretive criteria for disk diffusion susceptibility testing of sparfloxacin.司帕沙星纸片扩散法药敏试验的暂行解释标准。
J Clin Microbiol. 1993 Aug;31(8):2236-7. doi: 10.1128/jcm.31.8.2236-2237.1993.
2
Interpretive criteria for CI-960 (AM-1091, PD127391) disk diffusion tests using 5-microgram disks.使用5微克纸片进行CI-960（AM-1091，PD127391）纸片扩散试验的解释标准。
Diagn Microbiol Infect Dis. 1992 May-Jun;15(4):379-81. doi: 10.1016/0732-8893(92)90029-s.
3
Temafloxacin disk potency and tentative interpretive criteria for susceptibility tests.替马沙星纸片效价及药敏试验暂行解释标准。
J Clin Microbiol. 1989 Dec;27(12):2861-3. doi: 10.1128/jcm.27.12.2861-2863.1989.
4
Multi-center validation of proposed disk diffusion susceptibility testing interpretive criteria for lomefloxacin using more than 1,500 clinical isolates.使用超过1500株临床分离株对洛美沙星纸片扩散法药敏试验解释标准进行多中心验证。
Diagn Microbiol Infect Dis. 1996 Mar;24(3):169-72. doi: 10.1016/0732-8893(96)00019-3.
5
Reevaluations of disk diffusion susceptibility testing interpretive criteria for lomefloxacin and norfloxacin using fluoroquinolone-resistant isolates.
Diagn Microbiol Infect Dis. 1995 Apr;21(4):227-30. doi: 10.1016/0732-8893(95)00047-e.
6
Interpretive criteria for DU-6859a disk diffusion tests using 5-micrograms disks.使用5微克纸片进行DU - 6859a纸片扩散试验的解释标准。
Diagn Microbiol Infect Dis. 1994 Feb;18(2):125-7. doi: 10.1016/0732-8893(94)90078-7.
7
8
In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.针对在美国和加拿大分离出的24940种病原体的司帕沙星活性和抗菌谱的体外评估，最终分析。
Diagn Microbiol Infect Dis. 1998 May;31(1):313-25. doi: 10.1016/s0732-8893(97)00247-2.
9
Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin.测试厌氧细菌对两种氟喹诺酮类化合物（PD 131628和克林沙星）敏感性的方法。
J Antimicrob Chemother. 1993 Jun;31(6):893-900. doi: 10.1093/jac/31.6.893.
10
Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.利用美国190个医疗中心分离出的14000多种病原体的检测结果，对司帕沙星的活性和抗菌谱进行体外比较评估。SPAR研究小组。
Diagn Microbiol Infect Dis. 1997 Nov;29(3):173-86. doi: 10.1016/s0732-8893(97)81807-x.
引用本文的文献
1
Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates.在使用耐环丙沙星临床分离株预测组进行测试后，对左氧氟沙星和司帕沙星纸片扩散药敏试验标准的建议修改。
J Clin Microbiol. 1995 Jan;33(1):146-8. doi: 10.1128/jcm.33.1.146-148.1995.
本文引用的文献
1
In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent.新型喹诺酮抗菌剂司帕沙星的体外活性
J Antimicrob Chemother. 1990 Nov;26(5):667-76. doi: 10.1093/jac/26.5.667.
2
In vitro activity of sparfloxacin (AT-4140, CI-978, PD 131501), a new quinolone antimicrobial agent.新型喹诺酮抗菌剂司帕沙星（AT-4140、CI-978、PD 131501）的体外活性
Diagn Microbiol Infect Dis. 1990 Jul-Aug;13(4):345-8. doi: 10.1016/0732-8893(90)90029-u.
3
Interpretive criteria for disk diffusion susceptibility testing of sparfloxacin.司帕沙星纸片扩散法药敏试验的解释标准。
Eur J Clin Microbiol Infect Dis. 1991 Mar;10(3):163-6. doi: 10.1007/BF01964449.
4
In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.司帕沙星、妥舒沙星、环丙沙星和氟罗沙星的体外活性。
Antimicrob Agents Chemother. 1991 May;35(5):955-60. doi: 10.1128/AAC.35.5.955.
5
The penetration of sparfloxacin into human plasma and skin tissues.司帕沙星在人血浆和皮肤组织中的渗透情况。
J Antimicrob Chemother. 1991 Aug;28(2):313-4. doi: 10.1093/jac/28.2.313.
6
Pharmacokinetics and inflammatory fluid penetration of sparfloxacin.司帕沙星的药代动力学及炎性液体渗透情况
Antimicrob Agents Chemother. 1992 Nov;36(11):2444-6. doi: 10.1128/AAC.36.11.2444.
Zotero 插件